ADVANTAGES OP ANTI-VEGF THERAPY IN RETINOPATHY OP PREMATURE
Retinopathy of prematurity is one of the main causes of blindness and visual impairment in childhood. The study was conducted to improve the results of treatment of this disease, to evaluate the effectiveness of vascular endothelial growth factor (VEGF) inhibitors in the treatment of patients with retinopathy of prematurity with intravitreal administration. Such treatment was received by 154 premature infants with retinopathy with gestational age from 22 to 36 weeks and weight from 720 to 2560 g. The developed technique allowed to reduce the dose of the administered drug bevacizumab by 2 times, which reduces the number of potential complications and creates an opportunity for physiological retinal vascularization. The results obtained indicate a high (93,3%) effectiveness of vascular endothelial growth factor inhibitors in the treatment of aggressive forms of retinopathy of prematurity.